BRIEF—Movantik analysis reflects ability to ease opioid-induced constipation

Redhill Biopharma has presented three new analyses of Movantik (naloxegol) Phase III study data at PAINWeek 2021.

The results demonstrate rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged at least 65 and across both low- and high-dose opioid therapy.

Movantik, from Israel’s Redhill Biopharma, is the US market-leading oral peripherally acting mu-opioid receptor antagonist, approved to treat OIC in adults with chronic non-cancer pain.

Lynn Webster, pain researcher and clinician, and senior fellow at the Center of US Policy, said: “With up to 90% of older patients receiving opioids to help cope with chronic pain, and up to 86% of them suffering from symptoms of OIC, these new analyses are particularly important in helping these patients achieve satisfactory control of their pain without the added burden of OIC.”